Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial

BACKGROUND: Uncontrolled/refractory gout patients are recalcitrant/intolerant to oral urate-lowering therapies (ULTs), experiencing frequent gout flares, functionally limiting tophi, and low quality of life. Pegloticase lowers urate, but anti-pegloticase antibodies limit urate-lowering efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Botson, John K., Obermeyer, Katie, LaMoreaux, Brian, Zhao, Lin, Weinblatt, Michael E., Peterson, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793599/
https://www.ncbi.nlm.nih.gov/pubmed/36575505
http://dx.doi.org/10.1186/s13075-022-02979-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793599/
https://www.ncbi.nlm.nih.gov/pubmed/36575505
http://dx.doi.org/10.1186/s13075-022-02979-4

Ejemplares similares